In the Past 30 Days...
PER WEEK
PER POST
PER POST
In the last 30 days, the average company in this landscape has grown their audience by 0.2%. Abbott grew faster than everyone else, with 2.1% growth! On average, each post in this landscape earns more than 107.8 engagements. Abbott is topping the charts with more than 340.9 engagements per post on their 30 posts in the last 30 days.
930 Likes • 14 Comments
Every bigten school claims the most pride. Now's the time to prove it. The We Give Blood competition is back. Here's how to get involved: ✅ Step 1: Donate blood at any blood center or blood drive in the U.S. by Dec. 4 ✅ Step 2: Submit your donation for your Big Ten team at BigTen.org/Abbott or by …
840 Likes • 48 Comments
Big Ten country, here we come. This fall, we're traveling across the Big Ten to see which schools' fans, alumni, and students step up, give blood, save lives, and rise to the top. Think your team has what it takes to win? Prove it. Sign up to donate at BigTen.org/Abbott
282 Likes • 3 Comments
As Novartis turns 30, we went deeper into our history of doing what’s never been done. We opened the vaults of the Novartis Company Archives and revisited moments that span more than 250 years of discovery and innovation, from the dye factories along the Rhine to the breakthroughs that have helped change patients' lives around the …
211 Likes • 4 Comments
Imagine controlling a powerchair that accelerates like a rocket to 15.4 km/h, and making split-second tactical decisions on the court 🚀🏒. This #SMAAwarenessMonth, we are passing the mic to the incredible voices in the SMA community to share their passions. SMA My Way Champion Pia shares the experience of watching her daughter, Peppi, compete at the …
206 Likes • 1 Comments
From color chemistry to healthcare innovation, discover how Pure Prune and Brilliant Dolphin Blue helped shape a legacy of scientific discovery. Explore the story behind the innovations that helped build our heritage on Live.Magazine. Link in bio. #NovartisLive #30YearsOfNovartis
59 Reactions • 14 Comments • 9 Shares
As Novartis turns 30, we went deeper into our history of doing what’s never been done. We opened the vaults of the Novartis Company Archives and revisited moments that span more than 250 years of discovery and innovation, from the dye factories along the Rhine to the breakthroughs that have helped change patients' lives around the …
39 Reactions • 2 Comments • 27 Shares
Every Big Ten school claims the most pride. Now's the time to prove it. The We Give Blood competition is back. Here's how to get involved: ✅ Step 1: Donate blood at any blood center or blood drive in the U.S. by Dec. 4 ✅ Step 2: Submit your donation for your Big Ten team at BigTen.org/Abbott or …
39 Reactions • 4 Comments • 5 Shares
30 years of Novartis, powered by 250 years of innovation.
41 Reactions • 3 Comments • 2 Shares
Big Ten country, here we come. This fall, we're traveling across the Big Ten to see which schools' fans, alumni, and students step up, give blood, save lives, and rise to the top. Think your team has what it takes to win? Prove it. Sign up to donate at BigTen.org/Abbott
23 Reactions • 12 Comments • 7 Shares
Feeling nervous before a vaccine appointment? You're not alone. Sometimes getting a shot isn't easy, but our pharmacists can help make the experience a little easier.
29 Likes • 5 Retweets
Every dose of medicine you take is the final step in a long journey—one that runs through qualified suppliers, rigorous testing, and continuous monitoring. Pfizer's Bina Nair and Kenya Edmondson walk through what it takes to make sure every dose performs the same way, pic.x.com/Bl8hAKR6ks
28 Likes • 7 Retweets
250 years of American innovation have shown what’s possible when different minds and ideas come together. As we look to what’s next, Pfizer is proud to build on that spirit of innovation, continuing to advance science and explore what’s possible for the future of medicine. pic.x.com/js9psGjaGg
26 Likes • 7 Retweets
#GileadNews: The U.S. FDA approves first and only single-tablet regimen for the treatment of HIV in adults who are virologically suppressed, including those on complex multi-tablet regimens. Learn more: gilead.inc/4qGK5Yd pic.x.com/YvFPdwpYIz
21 Likes • 5 Retweets
As #ESCCongress 2026 returns to Munich, early diagnosis and treatment initiation remain the biggest opportunity to improve outcomes in ATTR-CM, an underdiagnosed cause of heart failure. Explore how the landscape has evolved and what needs to happen next: bit.ly/3UIiVV0 pic.x.com/YkdtiQ3CSb
10 Likes • 10 Retweets
A first-of-its-kind, two-in-one biowearable*: Meet our Libre Duo 10 Day system, now with U.S. FDA authorization. Diabetic ketoacidosis (DKA) is a serious health condition for people living with diabetes that can escalate quickly and lead to hospitalization in a matter of pic.x.com/DDk4AN95ck
The Social Media Benchmark Report
Ready to see how you stack up to your industry’s top social performers? Review the latest metrics on channels, engagement, post types, and more.